Delivering a holistic view of the pandemic, The Lancet HIV publishes original research, comment, and correspondence that unifies clinical, epidemiological, and operational disciplines across a single vision of health for those living with HIV. The Journal covers innovative treatments and the biological research underpinning such developments, novel methods of service delivery, and new ways of confronting HIV/AIDS worldwide.
Clinical Microbiology Reviews (CMR) analyzes the latest developments in clinical microbiology and immunology. Key topics include pathogenic mechanisms, individual and groups of microbial pathogens, clinical and laboratory aspects of newly recognized and reemerging infectious diseases, antimicrobial agents and their applications, and diagnostic laboratory technologies. Clinical and medical microbiologists, immunologists, epidemiologists, pathologists, public health workers, and infectious disease specialists all turn to the Journal to discover not only the current state of knowledge in the field, but also balanced, thought-provoking perspectives on controversial issues of the day.
Immunity publishes papers that report the most important advances in immunology research. The range of subjects includes, but is not limited to, immune cell development and senescence, signal transduction, gene regulation, innate and adaptive immunity, autoimmunity, infectious disease, allergy and asthma, transplantation, and tumor immunology.
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
Gastric Cancer, a joint official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, publishes significant studies related to stomach neoplasms. The Journal welcomes original articles, case reports, short communications, and technical notes, which will be peer-reviewed by the editorial board.
Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region. Original research articles, early reports, review articles, commentaries and editorials covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are all welcome.
Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.
The Cancer Journal: The Journal of Principles & Practice of Oncology provides an integrated view of modern oncology across all disciplines. The Journal publishes original research and reviews, and keeps readers current on content published in the book Cancer: Principles & Practice of Oncology.
Cancer survivorship is a worldwide concern; currently, there are 13 million cancer survivors in the US alone. The aim of the Journal of Cancer Survivorship is to provide a global forum for new knowledge related to cancer survivorship. The Journal publishes peer-reviewed papers relevant to improving the understanding, prevention, and management of the multiple areas related to cancer survivorship that can affect quality of care, access to care, longevity, and quality of life. It is a forum for basic research in humans (laboratory or clinical), clinical studies, systematic and meta-analytic literature reviews, policy studies, and in rare situations case studies as long as they provide a new observation that should be followed up on to improve outcomes related to cancer survivors.
Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The Journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.